Parmax Pharma Limited approved the allotment of 31,37,586 equity shares and 21,45,145 convertible warrants on a preferential basis. The Board sanctioned the issue on August 29, 2026, at an issue price of ₹36.50 per share or warrant.

The transaction raises ₹11,45,21,889 from the equity component alone. The convertible warrants carry the same exercise price and can be converted into equity shares within 18 months. The Company received in-principle approval from the Stock Exchange on August 21, 2026.

Allotment Structure

The preferential issue targets members of the non-promoter category. The equity shares allotted rank pari-passu with existing shares. The warrants are fully convertible into one equity share each.

Promoter Status Changes

Several allottees transitioned from the non-promoter (public) category to the promoter group following the allotment. Dhiren Chandulal Shah, Sunil Chinubhai Shah, Hiren Pravin Doshi, and Umang Alkesh Gosalia were reclassified as promoters.

Other individuals, including Sheetal Hiren Doshi and Nirmal Sunilbhai Shah, joined the promoter group. Urvi Manish Kothari, Mili Saumil Shah, and Fredun Nariman Medhora remained in the non-promoter category.

What the Numbers Show

The preferential issue significantly alters the promoter holding structure. Dhiren Chandulal Shah emerges as the largest single promoter stakeholder with a post-issue holding of 12.63%. This includes 604,190 newly allotted equity shares and 535,715 warrants.

Umang Alkesh Gosalia, the Managing Director, increased his holding to 6.01% through the allotment of 342,466 equity shares. He did not receive any warrants in this transaction. The combined promoter group exposure rises substantially due to these fresh capital infusions.